148 related articles for article (PubMed ID: 38708541)
21. [Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.].
Spagnolo F
Recenti Prog Med; 2021 Apr; 112(4):49e-52e. PubMed ID: 33877100
[TBL] [Abstract][Full Text] [Related]
22. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
[TBL] [Abstract][Full Text] [Related]
23. Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
Ngo P; Bycroft R
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527213
[TBL] [Abstract][Full Text] [Related]
24. The discovery and development of binimetinib for the treatment of melanoma.
Tran B; Cohen MS
Expert Opin Drug Discov; 2020 Jul; 15(7):745-754. PubMed ID: 32249628
[TBL] [Abstract][Full Text] [Related]
25. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
26. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With
Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA
J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871
[TBL] [Abstract][Full Text] [Related]
27. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
28. Development of encorafenib for BRAF-mutated advanced melanoma.
Koelblinger P; Thuerigen O; Dummer R
Curr Opin Oncol; 2018 Mar; 30(2):125-133. PubMed ID: 29356698
[TBL] [Abstract][Full Text] [Related]
29. Case series of BRAF-mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy.
Fujimura T; Yoshino K; Kato H; Fujisawa Y; Nakamura Y; Yamamoto Y; Kunimoto K; Ito T; Matsushita S; Maekawa T; Ohuchi K; Amagai R; Muto Y; Furudate S; Kambayashi Y; Hashimoto A; Aiba S
J Dermatol; 2021 Mar; 48(3):397-400. PubMed ID: 33179310
[TBL] [Abstract][Full Text] [Related]
30. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
31. Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
Khullar K; Hanft S; Mehnert JM; Weiner JP
Melanoma Res; 2021 Aug; 31(4):393-396. PubMed ID: 34054058
[TBL] [Abstract][Full Text] [Related]
32. Preclinical discovery and clinical development of encorafenib for the treatment of melanoma.
Okten IN; Ismail S; Withycombe BM; Eroglu Z
Expert Opin Drug Discov; 2020 Dec; 15(12):1373-1380. PubMed ID: 32720533
[TBL] [Abstract][Full Text] [Related]
33. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
34. Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Mian P; Meussen E; Piersma D; Lankheet NAG
Anticancer Drugs; 2021 Jun; 32(5):589-591. PubMed ID: 33587356
[TBL] [Abstract][Full Text] [Related]
35. Integrin-targeted quantitative optoacoustic imaging with MRI correlation for monitoring a BRAF/MEK inhibitor combination therapy in a murine model of human melanoma.
Kazmierczak PM; Burton NC; Keinrath G; Hirner-Eppeneder H; Schneider MJ; Eschbach RS; Heimer M; Solyanik O; Todica A; Reiser MF; Ricke J; Cyran CC
PLoS One; 2018; 13(10):e0204930. PubMed ID: 30281669
[TBL] [Abstract][Full Text] [Related]
36. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract][Full Text] [Related]
37. Encorafenib and Binimetinib: First Global Approvals.
Shirley M
Drugs; 2018 Aug; 78(12):1277-1284. PubMed ID: 30117021
[TBL] [Abstract][Full Text] [Related]
38. In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma.
Flaherty K
Clin Adv Hematol Oncol; 2017 Oct; 15(10):745-747. PubMed ID: 29040252
[No Abstract] [Full Text] [Related]
39. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
40. Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.
Trouiller JB; Nikolaidis GF; Macabeo B; Meyer N; Gerlier L; Schlueter M; Laramee P
Eur J Health Econ; 2024 Jun; 25(4):641-653. PubMed ID: 37433888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]